SCHEMBL26251001

SCHEMBL26251001

CCOC(=O)Cn1nc(C(F)(F)F)c2c1C(=O)[C@@H]1CC21

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.40
▸ CYP2C19 P33261 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ TRPM2 O94759 1/20 0.38
▸ GAA P10253 3/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HPGD P15428 3/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21420046 1.00 POLB (0.40) POLBCYP2C19MAPK1CYP2C9TSHR
SCHEMBL14487702 1.00 POLB (0.40) POLBCYP2C19MAPK1CYP2C9TSHR
SCHEMBL14487337 0.84 LMNA (0.47) TSHRGAAKDM4EALDH1A1HTT
SCHEMBL21420050 0.81 POLB (0.38) POLBCYP2C19MAPK1CYP2C9TSHR
SCHEMBL21420079 0.81 POLB (0.38) POLBCYP2C19MAPK1CYP2C9TSHR
SCHEMBL20371748 0.81 POLB (0.40) POLBCYP2C19MAPK1CYP2C9TSHR
SCHEMBL14555766 0.81 POLB (0.40) POLBCYP2C19MAPK1CYP2C9TSHR
SCHEMBL14487355 0.81 POLB (0.40) POLBCYP2C19MAPK1CYP2C9TSHR
SCHEMBL23793626 0.80 CYP2C19 (0.40) POLBCYP2C19MAPK1CYP2C9TSHR
SCHEMBL25457871 0.80 POLB (0.39) POLBCYP2C19MAPK1CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760746-B2 Methods and intermediates for preparing therapeutic compounds GILEAD SCIENCES, INC. (US) 2023-09-19 — — US disclosed
US-11760746-B2 Methods and intermediates for preparing therapeutic compounds GILEAD SCIENCES, INC. (US) 2023-09-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760746-B2 Methods and intermediates for preparing therapeutic compounds CYP11A1, CYP11B1, CYP11B2 POLB 379/4885CYP2C19 600/4885MAPK1 3385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback